Summit Therapeutics (SMMT) Fundamental Analysis: Revenue, Earnings & Valuation

2.24 / 10

Underperform

Fundamental score is 2.2/10, indicating underperformance. Interest coverage and Revenue‑MV are bullish, but high current‑liabilities ratio and weak PB‑ROE limit quality. Overall, fundamentals appear constrained and below expectations.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight78.36%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight1.08%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-8.93%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value79.06

Score1/3

Weight-12.50%

1M Return-1.69%

PB-ROE

Value16.11

Score0/3

Weight26.39%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.03

Score2/3

Weight-2.77%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-9.08%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.44%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-8.59%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight35.61%

1M Return4.00%

Is SMMT fundamentally strong?

SMMT scores 2.24/10 on fundamentals and holds a Premium valuation at present. Backed by its -206.10% ROE, 0.00% net margin, -13.62 P/E ratio, 22.31 P/B ratio, and -364.52% earnings growth, these metrics solidify its Underperform investment rating.